Alector Inc ALEC
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2019-02-07 |
| Shares Out. | 111,030,000 |
| Website | alector.com ↗ |
| Phone | 13026587581 |
| Employees | 103 |
| Revenue | $1.0M |
| Gross Profit | $1.0M |
| Net Income | -$22.9M |
| Free Cash Flow | -$173.2M |
| Total Assets | $239.9M |
| Total Liabilities | $229.5M |
| Equity | $10.4M |
About Alector Inc
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.
Alector Inc is a publicly traded company under the ticker symbol ALEC on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
14 analysts (2026-07-01)